---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-048090"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2024-11-29T23:59:59+00:00"
generated_at: "2026-05-29T12:49:29.992743+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma FY2024 net loss $867k, revenue $237k; cash only $716

## Summary
- Total revenues of $236,560 (incl. $110k related party); operating loss of $418,189.
- Net loss of $867,252; basic & diluted EPS of ($0.21) on 4.1M weighted avg shares.
- Cash and cash equivalents at Sept 30, 2024: just $716; total assets $177,611.
- Total liabilities $5.37M vs. stockholders deficit ($5.19M); accumulated deficit $20.6M.
- Company remains development-stage; no FDA approvals for any product candidates.

## SEC filing metadata
- accession: 0001493152-24-048090
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2024-11-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000149315224048090/0001493152-24-048090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000149315224048090/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-048090
- JSON: https://secwatch.observer/filing/0001493152-24-048090.json
- Plain text: https://secwatch.observer/filing/0001493152-24-048090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.